Cephalosporin

Lore & Background

The aerobic mold that yielded cephalosporin C was found in the sea near Cagliari, Sardinia, by Italian pharmacologist Giuseppe Brotzu in July 1945. Guy Newton and Edward Abraham at the Sir William Dunn School of Pathology at the University of Oxford isolated cephalosporin C.

Reader's Guide

Cephalosporins are bactericidal antibiotics that disrupt bacterial cell wall synthesis by mimicking the D-Ala-D-Ala site and irreversibly inhibiting penicillin-binding proteins. They are classified into generations, with first-generation agents active predominantly against Gram-positive bacteria, and later generations showing increased Gram-negative activity. Several cephalosporins with a methylthiotetrazole side chain can cause hypoprothrombinemia and a disulfiram-like reaction with alcohol. Resistance can involve reduced PBP affinity or acquisition of β-lactam-insensitive PBPs. Fifth-generation cephalosporins such as ceftaroline are effective against MRSA, Listeria, and Enterococcus faecalis, which are not treatable with earlier generations.

Did You Know?

• The aerobic mold yielding cephalosporin C was found in the sea near Cagliari, Sardinia, by Giuseppe Brotzu in July 1945.
• Cephalosporins with a methylthiotetrazole side chain can cause a disulfiram-like reaction with alcohol.

Origins: From Sardinian Waters to the Pharmacy Shelf

In July 1945, Italian pharmacologist Giuseppe Brotzu isolated an aerobic mold from seawater near Cagliari, Sardinia. That organism, belonging to the fungal genus Acremonium—earlier catalogued under the name Cephalosporium—produced a compound he identified as cephalosporin C, marking the birth of an entirely new antibiotic family. Cephalosporins belong to the broader β-lactam class of antibiotics and, together with their close relatives the cephamycins, form a structural subgroup known as cephems. Their origin in a marine fungus rather than a soil bacterium set them apart from penicillins and gave researchers a fresh chemical scaffold to explore. The Sardinian find thus opened a door that would eventually yield multiple generations of clinically vital drugs, reshaping how physicians treat bacterial infections worldwide.

Molecular Design and the Battle for the Cell Wall

At the heart of every cephalosporin molecule sits a six-membered dihydrothiazine ring, a structural feature that distinguishes the class from penicillins. The positions on this ring are not interchangeable: modifications at position 3 tend to shape how the drug behaves pharmacologically in the body, while alterations at position 7 generally tune its antibacterial potency, though exceptions to both rules exist. Once inside the body, cephalosporins act as bactericidal agents by targeting the peptidoglycan layer that gives bacterial cell walls their structural integrity. The final crosslinking step in peptidoglycan assembly is carried out by penicillin-binding proteins, which latch onto the D-Ala-D-Ala terminus of muropeptide precursors. Cephalosporins exploit this mechanism by mimicking that D-Ala-D-Ala site, thereby locking onto the PBPs and irreversibly blocking the crosslinking reaction. Without that crosslinking, the cell wall cannot maintain its architecture, and the bacterium ultimately lyses. This elegant molecular mimicry is the same fundamental strategy shared by all β-lactam antibiotics, yet the cephalosporin scaffold offers a distinct chemical landscape for drug designers to exploit.

Generational Evolution and the Clinical Toolkit

Cephalosporins are commonly organized into generations, a framework that tracks how each successive wave of compounds broadened antibacterial reach. First-generation agents, such as cefazolin and cefalexin, show their strongest activity against Gram-positive organisms including Staphylococcus and Streptococcus, making them workhorses for skin and soft-tissue infections and for preventing hospital-acquired surgical-site infections. As the generations advance, the spectrum tilts progressively toward Gram-negative bacteria, often at the cost of some Gram-positive coverage. Fourth-generation cephalosporins represent a notable shift, achieving what is described as true broad-spectrum activity spanning both major bacterial groups. Beyond their primary antimicrobial role, cephalosporins serve as a critical alternative for patients with penicillin allergies, owing to their structurally distinct β-lactam ring. They are eliminated primarily through the urine. It is worth noting that generational labels are not universally consistent: cefaclor, for instance, is grouped as first-generation in Japan but second-generation in the United States, and the very concept of a fourth generation is not formally recognized in Japanese pharmacology.

Safety Myths, Structural Hazards, and the Resistance Frontier

For decades, a widely repeated claim held that roughly ten percent of patients allergic to penicillins or carbapenems would also react to cephalosporins. More recent epidemiological research, however, paints a far more reassuring picture: cross-reactivity with second-generation and later cephalosporins is substantially lower, and a 2012 literature review concluded the risk with third- and fourth-generation agents is negligible. Even for first-generation drugs sharing similar R1 side-chains, the true figure appears closer to one percent. Separately, certain cephalosporins bearing a methylthiotetrazole side-chain—such as cefoperazone and cefotetan—can trigger hypoprothrombinemia and a disulfiram-like reaction with alcohol by inhibiting vitamin K epoxide reductase and aldehyde dehydrogenase, making concurrent alcohol consumption dangerous. On the resistance front, bacteria evade cephalosporins by altering PBP affinity or acquiring β-lactam-insensitive PBPs, and while the class is generally more resistant to β-lactamases than penicillins, strains of E. coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and others have nonetheless developed varying degrees of resistance.